Eternal Search · Ratings · Project Ratings
Research & Funding Infrastructure
Meta-science: tools, publishing, funding, and evaluation.
#OverallProjectSci / Brk / Inv
155.0NUS Academy for Healthy Longevity
The NUS Academy for Healthy Longevity appears to be a Singapore-based precision-geromedicine hub at NUS that combines clinical-trial infrastructure, biomarker-oriented research, education, and public-facing convening around healthy longevity. The strongest direct evidence is not intervention efficacy but organizational build-out: a clinical trial centre opened in 2025, multiple recruitment-stage or feasibility studies are described, and peer-reviewed outputs include a conceptual framework (HELO), a Singapore population survey on healthy-longevity knowledge and interest, and adjacent aging-biomarker studies. Most claims about impact, personalization, and biological-age reduction remain promotional, early-stage, or non-comparative rather than validated in robust human outcome trials.Sci 55.2Brk 51.3Inv 57.3
55%
→
250.4Eternal Search
Eternal Search is a live longevity-focused funding and intelligence platform operated by Open Longevity (California 501(c)(3) nonprofit) that claims to reduce manual opportunity discovery by using AI-assisted curation, verification, deduplication, and relevance scoring across grants, fellowships, infrastructure support, investors, and related field signals. The strongest evidence supports it as an operating research-and-funding infrastructure product with public listings, basic traction metrics, and an API-oriented roadmap; the weakest point is that its core accuracy, coverage, and time-saving claims are self-described rather than independently validated.Sci 49.1Brk 44.6Inv 55.0
50%
→
348.7Singularis: reforming the communication of scientific knowledge
Singularis is an early-stage scientific-knowledge platform that argues conventional papers are a bottleneck for both human readers and AI systems, and proposes converting papers into structured argumentation graphs and nanopublication-like units that link hypotheses, methods, results, conclusions, and evidence. The concrete product evidence is a beta system for PDF upload, knowledge-graph visualization, and graph-based chat, plus public claims about AI-generated paper graphs and source-linked annotations. The core idea is plausible as research infrastructure, but current evidence shows positioning and prototype functionality more clearly than validated accuracy, adoption, or field-level impact.Sci 45.9Brk 55.5Inv 47.0
49%
→
445.9Pentara Brain Stride
Pentara Brain Stride appears to be a clinical-trial biostatistics and data-integrity offering focused on neurodegenerative disease studies, especially regulatory-facing trial design, analysis, and fraud detection. The core claim is not a new therapy but that better endpoint selection, statistical design, programming, data management, and anomaly detection can improve the truthfulness and decision value of brain-related trials. The evidence supports domain specialization and relevant personnel, but it is mostly self-description from company pages rather than independent validation, and no verified outcome metrics are provided.Sci 49.6Brk 31.9Inv 51.5
46%
→
543.2First Approval
First Approval appears to be an early-stage scientific data publishing platform for biology and longevity-adjacent research, centered on structured dataset annotation, decentralized/encrypted storage, customizable licensing, DOI-linked publication, and incentive mechanisms for sharing. The strongest project-specific evidence points to platform positioning and a 2025 student BioData Competition run with Open Longevity, but the available record is mostly promotional and organizational copy; key public pages were not accessible in the capture, and there is no independent evidence here of meaningful adoption, data quality improvement, monetization, or research impact.Sci 43.4Brk 42.6Inv 43.4
43%
→
641.9R42 Group
R42 Group appears to be a U.S.-based, founder-led venture platform and family-office-derived group centered on AI, biotech, and longevity, with an adjacent education/community arm (R42 Institute). The strongest evidence supports investing activity, network-building, and public positioning around AI-plus-longevity rather than validated scientific breakthroughs or clinical outcomes. Reported signals include a $16M AI and Longevity Fund, named investments such as Fountain Therapeutics and Healx, and a 2025 XPRIZE Healthspan semifinalist mention for an R42 approach described as gene therapy plus AI-guided systems biology, but most claims are self-reported, interview-based, directory-sourced, or promotional.Sci 29.4Brk 40.5Inv 53.7
42%
→
740.2Omega-Point
Omega-Point is a self-described AI experiment-design platform for longevity and biotech research that claims to turn a one-sentence scientific goal into a fully specified lab experiment via a nine-agent reasoning pipeline in about 10 minutes, producing requirement decompositions, frontier questions, competing hypotheses, and S-I-M-T protocol details. The core promise is plausible as research infrastructure, but the evidence here is almost entirely project marketing copy plus adjacent field-context preprints and patents; there is no independent validation, no benchmark against human experimental design, and no shown evidence that its outputs improve real laboratory outcomes.Sci 33.6Brk 44.0Inv 43.5
40%
→
834.5DTL
DTL appears to be a UK-based longevity market-intelligence product from First Longevity / Longevity.Technology, positioned as an AI-enabled, structured data and analysis layer over longevity biotech companies, drug assets, and related signals such as trials, financing, IP, partnerships, and talent. The concrete claimed output is decision support for investors, pharma BD, and operators through searchable datasets, custom reports, and a chatbot over a live longevity corpus. The evidence supports product positioning and claimed use cases, but it is mostly self-published marketing and partnership coverage with no independent validation of data quality, model performance, user outcomes, or commercial traction.Sci 29.8Brk 29.2Inv 42.0
35%
→
933.8Gobal Health Span Extension
Global Health Span Extension appears to be a Felix Platter-affiliated healthy-aging/healthspan initiative or consortium, but the direct project evidence is thin: the Felix Platter site mainly shows a navigation-level reference to a “Global Health Span Extension Consortium” rather than a substantive project description. The strongest adjacent evidence comes from the DO-HEALTH program and related Felix Platter / University of Zurich geriatrics work on vitamin D3, omega-3, and simple home exercise in generally healthy adults aged 70+, which supports a clinical healthy-aging context but does not, by itself, prove this specific project’s methods, governance, or outcomes.Sci 28.9Brk 31.3Inv 39.8
34%
→
1031.0FuturVille
FuturVille is a for-profit Canadian project positioning itself as a builder of "healthy longevity villages," with VulcanVille in Vulcan, Alberta presented as the first prototype: a 53-63 acre mixed-use site with 300+ dwelling units, wellness and retreat facilities, commercial space, and related development/investment offerings. The core claim is that village design, services, and community structure can add 10+ healthy years, but the current evidence is mostly self-published marketing, promotional social posts, and a single University of Calgary market-demand capstone rather than independent evidence of health, operational, or financial outcomes.Sci 23.6Brk 35.5Inv 34.7
31%
→
1122.6Beat-FSHD
Beat-FSHD appears to be a patient-facing FSHD support, education, advocacy, and news website rather than a research or therapeutic program. The available evidence supports intended functions such as support groups, educational materials, community forums, local events, newsletters, contact channels, and product recommendations, but the strongest project-specific credibility signals are weak: the site shows placeholder-style content, inconsistent author attribution, and inconsistent contact details, with no demonstrated clinical, scientific, or operational outcomes in the provided record.Sci 19.2Brk 17.6Inv 28.8
23%
→
1210.8Healthspan Quest
Healthspan Quest appears, on the available evidence, to be a Valley Christian Schools student team in the 2024-25 XPRIZE Healthspan competition rather than a validated longevity research program or venture. The strongest direct evidence is a school-hosted AMSE page stating the team ranked in the Top 100 and aimed to "redefine aging and extend healthy, high-quality years of life," but no technical method, personnel, data, publication, or outcomes are provided; the root `vcs.net` URL also creates a material project-identity mismatch risk because much of the surrounding evidence points to a K-12 school site, not a dedicated healthspan project.Sci 5.2Brk 10.8Inv 15.7
11%
→
132.7Team NovaVita
Available evidence does not substantiate Team NovaVita as a distinct longevity project. The only direct project signals are social-media posts signed “TEAM NOVAVITA ’25” tied to student-hall leadership and community communications, while Peking University materials provide only broad institutional context and no verified link to NovaVita’s work. No primary evidence shows a longevity hypothesis, research program, product, dataset, trial, or measurable outcome.Sci 0.6Brk 0.9Inv 5.7
3%
→